Literature DB >> 28012648

Impact of vasomotion type on prognosis of coronary artery spasm induced by acetylcholine provocation test of left coronary artery.

Eun Mi Lee1, Man Ho Choi2, Hong Seog Seo3, Hyun Ki Kim1, Nam-Ho Kim1, Cheol Ung Choi4, Jin Won Kim4, Hong Euy Lim4, Eung Ju Kim4, Seung-Woon Rha4, Chang Gyu Park4, Dong Joo Oh4.   

Abstract

BACKGROUND AND AIMS: The impact of vasomotion types on long-term clinical outcomes in patients with coronary artery spasm (CAS) induced by the acetylcholine provocation test (ACH-test) remains unclear.
METHODS: We evaluated 4644 consecutive patients with typical resting chest pain (CP), but no angiographically significant coronary artery lesion (<50% stenosis), who underwent an ACH-test. According to their vasomotor response, patients were categorized into four types: normal vasomotion (no CP, no ischemic electrocardiographic changes, and no vasoconstriction), microvascular spasm (CP with <75% vasoconstriction but with CP relief after nitroglycerin infusion), epicardial spasm (CP with ≥75% vasoconstriction), and ACH-test inconclusive (vasoconstriction and/or electrocardiographic changes, but no CP). We investigated CP recurrence requiring follow-up angiography and major adverse cardiovascular events (MACEs) during 5 years.
RESULTS: CP recurred in 7.9% of patients and was more frequent in abnormal vasomotion types (normal vasomotion, microvascular spasm, epicardial spasm, and inconclusive type: 5.4%, 9.8%, 10.9%, and 8.2%, respectively, log-rank p = 0.009). In multivariate analysis adjusted for medication use after the ACH-test, vasomotion subtype was not an independent predictor, whereas male sex, fixed lesion on baseline angiography, and medications including calcium channel blockers (CCBs), nitrates, and statins were independent positive predictors for recurrent CP. Alcohol consumption at the initial interview was a negative predictor. MACEs were observed in 1.6%, and the incidence was similar among subtypes (p = 0.421).
CONCLUSIONS: Recurrent CP and long-term outcomes are independent of vasomotion subtypes, but long-term use of CCBs, nitrates, and statins is a significant predictor for recurrent CP.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Acetylcholine provocation test; Coronary artery spasm; Long-term clinical outcome; Vasomotion type

Mesh:

Substances:

Year:  2016        PMID: 28012648     DOI: 10.1016/j.atherosclerosis.2016.09.015

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  4 in total

1.  Clinical, angiographic and echocardiographic correlates of epicardial and microvascular spasm in patients with myocardial ischaemia and non-obstructive coronary arteries.

Authors:  Rocco Antonio Montone; Giampaolo Niccoli; Michele Russo; Marta Giaccari; Marco Giuseppe Del Buono; Maria Chiara Meucci; Filippo Gurguglione; Rocco Vergallo; Domenico D'Amario; Antonino Buffon; Antonio M Leone; Francesco Burzotta; Cristina Aurigemma; Carlo Trani; Giovanna Liuzzo; Gaetano A Lanza; Filippo Crea
Journal:  Clin Res Cardiol       Date:  2019-07-03       Impact factor: 5.460

2.  The multi-vessel and diffuse coronary spasm is a risk factor for persistent angina in patients received anti-angina medication.

Authors:  Sang-Ho Park; Byoung Geol Choi; Seung-Woon Rha; Tae Soo Kang
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.889

3.  Haemodynamic characterisation of different endotypes in coronary artery vasospasm in reaction to acetylcholine.

Authors:  Rutger G T Feenstra; Coen K M Boerhout; Caitlin E M Vink; Janneke Woudstra; Marianne E Wittekoek; Guus A de Waard; Yolande Appelman; Etto C Eringa; Koen M J Marques; Robbert J de Winter; Tim P van de Hoef; Marcel A M Beijk; Jan J Piek
Journal:  Int J Cardiol Heart Vasc       Date:  2022-08-13

4.  Sex Difference in Coronary Artery Spasm Tested by Intracoronary Acetylcholine Provocation Test in Patients with Nonobstructive Coronary Artery Disease.

Authors:  Ji Young Park; Se Yeon Choi; Seung-Woon Rha; Byoung Geol Choi; Yung-Kyun Noh; Yong Hoon Kim
Journal:  J Interv Cardiol       Date:  2022-09-09       Impact factor: 1.776

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.